Evidence Based Deprescribing Guideline Symposium 2018

Monday, March 26th – Wednesday, March 28th 2018
Ottawa Conference and Event Centre
200 Coventry Road, Ottawa, Ontario Canada

The Bruyere Deprescribing Guidelines Research Team is hosting the Evidence Based Deprescribing Guideline Symposium 2018, March 26-28, 2018 in Ottawa, Canada. The symposium centers on sharing experiences and building momentum for deprescribing guideline development, implementation, education and research, allowing attendees to interact with high-quality content, network with colleagues and discover innovative developments in deprescribing guideline use.

Monday, March 26, 2018
Focus: Developing GRADE evidence- based deprescribing guidelines
Target audience: Current clinical guideline developers and people interested in developing deprescribing recommendations

Tuesday, March 27, 2018
Focus: Implementing evidence-based deprescribing guidelines
Target audience: Health care professionals, policy makers and members of the public interested in implementing deprescribing guidelines

Wednesday, March 28, 2018
Focus: Developing deprescribing guideline curricula; evaluating deprescribing guideline impact
Target audience: Educators and researchers

With over 150 participants expected to attend, you will be joined by:

  • Educators, policymakers, health providers and senior decision makers in the health care system
  • Physicians, pharmacists, nurse practitioners, and other health professionals
  • Representatives of patient care groups
  • Researchers

Register Here

Monday, March 26th 2018

Tuesday, March 27th 2018

7:45 – 8:30 Registration and breakfast
8:30 – 9:15 Welcome Address: Inaugural experiences developing deprescribing guidelines

Barbara Farrell, BScPhm, PharmD, FCSHP
Scientist, Bruyère Research Institute

Over the last five years, a methodology for developing evidence-based deprescribing guidelines has been proposed and used to generate four deprescribing guidelines. In this presentation, Dr. Farrell will discuss progress with the methodology and introduce the goals of the symposium.


9:15 – 10:00 Keynote: Why do we need a high quality method for developing deprescribing recommendations?

Kevin Pottie, MD, MClSc, CCFP, FCFP
Scientist, Bruyère Research Institute and GRADE Working Group methodologist

Kevin Pottie will discuss the value of evidence based guidelines versus expert opinion based guidelines. The crux of the discussion will focus on the science and rigour of systematic reviews and systematic guideline development for clinical guidelines, curriculum and policies. The perspectives of the Guidelines International Network Methods Working Group and the GRADE Methods Working Group will inform this presentation and encourage discussion about the central role for transparent, trustworthy and rigorous clinical practice guidelines for the deprescribing field.

10:00 – 10:15 Morning Break
10:15 – 11:45 How do we make sure guidelines are developed efficiently and effectively while meeting the needs of users?

Panel discussion:

  • Health care provider perspective – Candra Cotton, BSc Pharm, BSc Nutrition, clinical pharmacist at the Dr. Everett Chalmers Regional Hospital
  • Patient/public perspective – Johanna Trimble, Member, Patients for Patient Safety Canada and the BC Patient Voices Network
  • Payor perspective – Ned Pojskic, PhD, Pharmacy Strategy Leader, Green Shield Canada (GSC)
  • Policy perspective Barry Jones, BPharm, Senior Policy Analyst, Health Canada

Developing evidence-based guidelines takes time and energy. The perspectives of users are important to ensure that their needs are met by the guidelines that are developed. This session will help us understand the balance between rigorous guideline development and usefulness.

11:45 – 12:00 Instructions for small working group afternoon discussions
12:00 – 1:00 Lunch Break
1:00 – 2:30 Small working group discussions
  • Getting started on an evidence-based clinical guideline (choice of priority therapeutic topic areas – e.g. statins, opiods)
    Lisa McCarthy, BScPhm, PharmD, MSc, Scientist, Women’s College Research Institute at Women’s College Hospital, Lise Bjerre, MD, PhD, CCFP, Scientist, Bruyère Research Institute, and Feng Chang, RPh, BScPhm, PharmD, Associate Professor, School of Pharmacy, University of WaterlooThese workshops will meet the needs of those who would like to start developing a deprescribing guideline. Workshops will be organized by therapeutic category (e.g. statins, opioids). Additional topics may be chosen depending on attendee interest. Participants will use a Deprescribing Guideline Development guide to walk through steps in the development process, which include: identify potential guideline development team members, target funders, generate a PICO question, discuss methods for identifying relevant content such as benefits/harms of continuing the medication, or reducing/stopping it and to generate relevant clinical consideration questions. Each group will develop a plan to continue work on the topic following the symposium.
  • Incorporating deprescribing recommendations within existing clinical practice guidelines
    Carlos R. Fernandez, BSc(Pharm), PharmD, Health Outcomes Research Consultant.
    Most currently available prescribing guidelines do not incorporate deprescribing recommendations. The development of stand-alone evidence-based deprescribing guidelines is moving forward but this approach is expensive and time-consuming. In this session, we will brainstorm about advocacy options that could be directed toward clinical guideline developers to facilitate inclusion of deprescribing recommendations within prescribing guidelines and how such initiatives could be funded.
  • Planning a GRADE deprescribing special interest group
    Lisa Dolovich BScPhm, PharmD, MSc, Ontario College of Pharmacists Professorship in Pharmacy Practice, Leslie Dan Faculty of Pharmacy, University of Toronto and Kevin Pottie, MD, MClSc, CCFP, FCFP, Scientist, Bruyère Research Institute, GRADE Working Group methodologist
    Those who are already skilled at developing evidence-based guidelines will be interested in exploring how GRADE can be applied to deprescribing and whether modifications to GRADE tables or aspects of literature synthesis are needed. The goal for this session is to arrive at a process for completing an application for a GRADE Deprescribing Special Interest Group
2:30 – 2:45 Afternoon Break
2:45 – 4:00 Moving deprescribing guideline initiatives forward

Panel discussion:

  • Therapeutic topics perspective
  • Existing clinical practice guidelines perspective
  • GRADE deprescribing special interest group perspective

This panel discussion will include perspectives from the leads of the different working groups, followed by a moderated discussion culminating with the identification of next steps to move guideline initiatives forward internationally.

4:00 – 4:15 Reflection and next steps

Lisa McCarthy, BScPhm, PharmD, MSc
Scientist, Women’s College Research Institute at Women’s College Hospital

We will end the day with a summary of the day’s learnings and an introduction to how this material will be considered during the remaining days of the symposium.

7:45 – 8:30 Registration and breakfast
8:30 – 8:45 Welcome

James Conklin, PhD
Associate Professor, Applied Human Sciences at Concordia University

We will set the stage for the day by illustrating that the problem of polypharmacy is a human problem that can have a devastating impact on people who are struggling with difficult health conditions, an impact that spreads to family members and broader social networks, and that produces challenges for health care providers.

8:45 – 9:30 Keynote: The long and winding road: moving a good idea into routine practice

Frank Federico, RPh
Executive Director, Strategic Partners, Institute for Healthcare Improvement (IHI)

Deprescribing guidelines have the potential to help with the needs of a high performing health care system – including better access, improved quality and greater efficiency. The IHI International Program in Health Policy and Practice Innovations selected deprescribing guidelines as a key innovation to implement in the US. In this presentation, Frank Federico will contextualize deprescribing within the overall patient safety movement and provide an overview of the transferability of the guidelines within the US IHI Innovators Network.

9:30 – 10:30 Learning from implementation experiences in different care contexts

Panel discussion:

  • Vittorio Maio, PharmD, MS, MSPH, Thomas Jefferson University, the Italian experience
  • Innovator Network member, Institute for Healthcare Improvement, the IHI experience in the United States
  • Barbara Farrell, BScPhm, PharmD, FCSHP, Bruyère Deprescribing Guidelines team, the Ontario experience

Three panelists will share their experiences in implementing deprescribing guidelines in Italian, US and Canadian health care contexts including family practices, long-term care, and institutional practices. Panelists will highlight their successes and setbacks, and will summarize key learnings. Audience members will have the opportunity to ask questions and offer comments.

10:30 – 11:00 Morning Break
11:00 – 12:15 Deprescribing guideline implementation – what works and what doesn’t: Opportunities to learn from each other

Small group discussions

Participants will be invited to gather at tables to discuss a variety of topics related to implementing deprescribing guidelines health practices . Each table will have a facilitator who will help to guide the discussion and a note-taker who will capture salient points. The discussions offer an opportunity for participants to broaden their networks and to learn together about implementation opportunities and challenges. The notes from the sessions will be summarized in a report that will be made available to all participants shortly after the conclusion of the symposium.

12:15 – 1:00 Lunch Break
1:00 – 1:30 Moving deprescribing forward – what needs to happen so deprescribing becomes a routine part of health care?

Alan Cassels, CD, MPA
Drug Policy Researcher, Faculty of Human and Social Development, University of Victoria

Alan Cassels has seen the problems of polypharmacy through three lenses–as a journalist, researcher and, most recently, as a family caregiver. He’ll share what he’s learned in publicizing the problems of polypharmacy, his research from interviewing clinicians around challenges in deprescribing, and how knowledge, courage and compassion may not even be enough to overcome real-time barriers to cutting back on his mother’s medications. Alan will make suggestions on what he thinks is needed to overcome the barriers to reducing polypharmacy, including systems-level structures that continue to feed far too much medicine to our seniors with all the harms, costs and medical consequences that result.

1:30 – 2:30 Concurrent sessions

Moving forward across health care contexts – TBC

What role can policy play in the implementation of deprescribing initiatives?
Justin Turner, BPharm, MClinPharm, PhD, Senior Advisor, Science Strategy, Canadian Deprescribing Network (CaDeN), Postdoctoral Fellow, Centre de recherche Institut universitaire de gériatrie de Montréal
This session will investigate the potential for policy to facilitate deprescribing and how we can influence policy makers to prioritise deprescribing. An overview of international policies that have been implemented to reduce potentially inappropriate medications will be presented. An entertaining and interactive discussion will identify policies with potential to encourage or facilitate the implementation and use of deprescribing guidelines in Canada and beyond.

Engaging with the public – aiming for collaborative care for deprescribing
Emily Reeve, BPharm(Hons), PhD, Research Fellow, Kolling Institute of Medical Research, Northern Clinical School, Faculty of Medicine, The University of Sydney
This session looks at the importance of public engagement to facilitate the adoption and use of deprescribing guidelines. Key principles and frameworks of public engagement will be discussed with presentations from consumers. This session will provide an opportunity for attendees (particularly members of the public) to provide feedback, comments and ask questions about public engagement in deprescribing guidelines.


2:30 – 3:00 Afternoon Break
3:00 – 3:30 Creating sustainability for deprescribing guideline implementation

Panel discussion:

  • Collaboration and communication within and across contexts of care
  • Policy initiatives needed for deprescribing guideline adoption
  • Strategies for public engagement and involvement

Three expert panelists who led the concurrent sessions will share ideas about the role and importance of strategies that aim at implementing deprescribing guidelines within and across contexts of care, influencing policy agendas, and promoting public engagement and involvement. The panelists will share thoughts that came up during the concurrent session discussions, and participate in a further discussion with the audience.

3:30 – 4:00 Why deprescribing is a “wicked” problem and what to do about it

James Conklin, PhD
Associate Professor, Applied Human Sciences at Concordia University

James Conklin will explain why the implementation of deprescribing guidelines is an adaptive challenge that will require a process that combines multiple tactics that unfold over a lengthy period of time. He will summarize some of the highlights from the earlier sessions, and will emphasize the importance of targeted actions that occur within the scaffolding offered by supportive groups and organizations such as IHI and CFHI. Members of the audience will have the opportunity to offer brief concluding comments.

4:30 – 6:00 CaDeN Sponsored networking reception – wine and cheese

The Canadian Deprescribing Network (CaDeN) is a group of health care leaders, clinicians, decision-makers, academic researchers and patient advocates working together to mobilize knowledge and promote the deprescribing of medication that may no longer be of benefit or that may be causing harm.

Wednesday, March 28th 2018

7:45 – 8:30 Registration and breakfast
8:30 – 8:45 Welcome

Lalitha Raman-Wilms, BScPhm, PharmD, FCSHP
Professor and Dean, College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba

The day will highlight two components: the importance of including deprescribing guideline development and the process of deprescribing into health professional curricula, as well as the effective evaluation of guideline implementation and quality improvement in clinical practice.

8:45 – 9:30 Keynote: Deprescribing guidelines education and research – the interplay and the way to move forward
  • Lisa Dolovich, BScPhm, PharmD, MSc
    Ontario College of Pharmacists Professorship in Pharmacy Practice, Leslie Dan Faculty of Pharmacy, University of Toronto
  • Ivy Oandasan, MD, CCFP, MHSc, FCFP
    Associate Director, Academic Family Medicine, College of Family Physicians of Canada

In this session Ivy Oandasan and Lisa Dolovich will each present some reflections on the relationship between research and education including how the deprescribing guidelines or deprescribing research in general can influence curricular planning and how education and training can encourage deprescribing research. Ivy and Lisa will each take 10-15 minutes to present their thoughts followed by a 15-20 minute guided casual discussion that will engage with the larger group.

9:30 – 12:00 Educator breakout stream: Learning to be a better prescriber

Zubin Austin, BScPhm MBA MISc PhD FCAHS
Professor and Murray Koffler Chair in Pharmacy Management

Working group: How do clinicians learn to prescribe and deprescribe?

This session will start with a presentation by Zubin Austin, followed by discussions in small and large groups. Participants will reflect upon the processes by which health care professionals learn to become prescribers and consider what are quality prescribing practices. This will lead to a discussion of deprescribing and strategies for teaching and of this within curricula.

9:30 – 12:00 Researcher breakout stream

Participatory vs Expert-led Evaluation: competing factors in guideline implementation and evaluation
Malcolm Maclure, ScD
Academic Chair in Patient Safety and Professor in the Department of Anesthesiology, Pharmacology and Therapeutics at UBC
Dr. Maclure will outline approaches to evaluating guideline/quality improvement implementation (e.g. design methods and outcomes). He will discuss approaches to capturing process and qualitative experiences, quality improvement, clinical and economic outcomes, while promoting participatory evaluation. This will be illustrated with an antipsychotic deprescribing case study from British Columbia with several approaches to evaluation and challenges faced striving for rigour at the same time as engaging clinicians.

Deprescribing Research: Past and Future
Wade Thompson, PharmD, MSc, PhD (Candidate)
University of South Denmark
Wade Thompson will provide a brief overview of deprescribing research (e.g. clinical, economic, values/preferences) to date, with a focus on gaps in evidence . He will also highlight work done by researchers at Queen’s University Belfast on developing core outcome sets for research on polypharmacy and deprescribing in older persons.

World Café: Deprescribing research priorities and important outcome measures for developing guidelines
The world café format allows for sharing of knowledge and creation of new ideas using iterations of small group discussions. In this world café, Emily Reeve and Wade Thompson will facilitate discussion on two key questions: (1) What are priorities for future deprescribing research (e.g. drug classes, patient populations, types of studies)? (2) What outcome measures are important to inform future deprescribing guidelines? Session attendees will work together in small groups to share and develop thoughts on these questions and then come together in a large group to discuss and synthesize their ideas.

12:00 – 1:00 Lunch Break
1:00 – 2:30 Educator breakout stream continued

Developing a national approach to quality prescribing and deprescribing
Zubin Austin, BScPhm, MBA, MISc, PhD, FCAHS
Professor and Murray Koffler Chair in Pharmacy Management

Working group: Developing a national approach to quality prescribing and deprescribing.
As a guide to support the development of deprescribing curricula in health professional education, discussion will include competencies, highlights of effective teaching practices, assessment methods, and how to influence development of curricular change. Who should contribute to the drafting of the white paper and its endorsement and uptake, as well as dissemination and scholarship, will be discussed.

1:00 – 2:30 Researcher breakout stream continued

Evaluating deprescribing guideline implementation initiatives
Rapid fire presentations: Ongoing research
Frank Moriarty, BSc (Pharm), MPharm, PhD, MPSI
HRB Centre for Primary Care Research, Ireland
Selected Day 3 registrants will be invited to present short, high-level overviews of completed, ongoing or upcoming work in evaluating deprescribing initiatives. Frank Moriarty will facilitate discussion between presenters and other session attendees to allow opportunities to learn from the experiences of others and for future collaboration on evaluation projects.

World Café: Evaluating the implementation and effectiveness of deprescribing guidelines
Emily Reeve, BPharm(Hons), PhD, and Wade Thompson, PharmD, MSc
In this final café, Emily Reeve and Wade Thompson will facilitate discussion on identifying methods and approaches for evaluating implementation of deprescribing initiatives moving forward. Discussions will focus on topics such as study design, evaluating the process and outcomes of implementation and what ‘successful’ implementation might look like.

2:30 – 3:00 Afternoon Break
3:00 – 3:45 Reconvening for summary, reflection and next steps
  • Educator stream: Zubin Austin, BScPhm, MBA, MISc, PhD, FCAHS, Professor and Murray Koffler Chair in Pharmacy Management
  • Researcher stream: Frank Moriarty, BSc (Pharm), MPharm, PhD, MPSI, HRB Centre for Primary Care Research, Ireland
  • Reflection and next steps: Lalitha Raman-Wilms, BScPhm, PharmD, FCSHP, Professor and Dean, College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba

Leads from each of the Educator and Research streams, Zubin Austin and Frank Moriarty, will share a summary of key learnings from the day. We end the day with Lalitha Raman-Wilms speaking to the interplay between research and teaching and implications for future work related to deprescribing in these areas.

3:45 – 4:00 Closing remarks

Barbara Farrell, BScPhm, PharmD, ACPR, FCSHP
Scientist, Bruyère Research Institute



Alan Cassels, CD, MPA

Drug Policy Researcher with the Faculty of Human and Social Development at the University of Victoria

Alan Cassels is an author, drug policy researcher and Adjunct Professor in the School of Human and Social Development at the University of Victoria. Since 1994 he has worked on a research and evaluation studies focusing on drug benefits policies and examining how clinical research and experience on drugs is communicated to policy-makers, prescribers and consumers. He has acted as a project manager, principal investigator and co-investigator on studies related to drug plan policies, the management of private drug benefits, seniors’ attitudes towards drug coverage, and the media reporting of pharmaceuticals.

He is an expert advisor with Canada’s Evidence Network, a reviewer and blogger for HealthNewsReview.org which evaluates medical news reporting, and is the senior vice president of research for Quizzify.com, a company that teaches employees how to buy and use healthcare.

Barbara Farrell, BScPhm, PharmD, FCSHP

Dr. Barbara Farrell is a Scientist with the Bruyère Research Institute and CT Lamont Primary Health Care Research Centre. She is an Assistant Professor with the Department of Family Medicine, University of Ottawa and Adjunct Assistant Professor with the School of Pharmacy, University of Waterloo. She maintains a clinical practice as a pharmacist in the Bruyère Geriatric Day Hospital and is Clinical and Research Coordinator in the Pharmacy Department at Bruyère Continuing Care.

Dr. Farrell’s research interests include evaluating evolving pharmacist roles, educational needs of pharmacists and innovative models to improve medication-related care for the elderly.In 2011, she was named the Canadian Pharmacist Association’s “Pharmacist of the Year.”


Barry Jones, BPharm, Senior Policy Analyst, Health Canada

Barry Jones graduated with a Pharmacy degree at the University of London, UK. He spent several years as the Chief Pharmacist for Phoenix Group Pharmacies in Bermuda, before operating a successful Pharmacy business there. He is a former president of the Bermuda Pharmaceutical Association. Since returning to Canada with his family, Barry has been employed with Health Canada and has worked in areas of pre-market activities, post-market surveillance and controlled substances. Presently, Barry is a Senior Policy Analyst with the Office of Pharmaceutical Management Strategies (OPMS) within the Strategic Policy Branch (SPB). His areas of expertise include expensive drugs for rare diseases (orphan drugs), personalised medicine (and targeted therapies), pricing of pharmaceuticals, market access and R&D strategies, biosimilars, and free trade agreements.

Carlos R. Fernandez, BSc(Pharm), PharmD

Health Outcomes Research Consultant

Dr. Fernandez is a graduate of Dalhousie University College of Pharmacy (1990 & 1998), and Wayne State University (1996). He completed post-doctoral training in Geriatric Clinical Pharmacology, Epidemiology and Quantitative Research methods in the Division of Geriatric Medicine, Dalhousie University. He has 28 years professional experience including community pharmacy, hospital pharmacy, long-term care, academia, neuroscience pharmaceutical industry research and development, and primary care. His areas of expertise include geriatrics, epidemiology, Alzheimer’s disease and related disorders, psychiatry, sleep disorders, and neuropsychopharmacology.

As an independent Health Outcomes Research Consultant, Dr. Fernandez provides consulting services to clients in Canada, US, and UK in areas such as research design & analysis, pharmacoepidemiology, drug safety, clinical pharmacology, disease matter expertise, and in clinical outcome measures such as patient reported outcome measures.

Emily Reeve BPharm (Hons) PhD

Emily Reeve’s research focuses on optimizing medication use in older adults and people with dementia. Emily is a qualified pharmacist with experience working as a clinical pharmacist at the Royal Adelaide Hospital. She completed her doctoral training at the University of South Australia in 2013 and was awarded the medal for her thesis from the School of Pharmacy and Medical Sciences. Emily is currently an NHMRC-ARC Dementia Research Fellow (commenced 2016). The project is being conducted in collaboration with the Deprescribing in the Elderly Project group at the Bruyère Research Institute.

Dr Reeve was the guideline lead for the Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine.

Feng Chang, BScPhm, PharmD

Associate Profession School of Pharmacy, University of Waterloo

Dr. Chang is a clinical pharmacist specializing in geriatric pharmacotherapy. Her research interests include caring for vulnerable older adults in primary care settings, particularly older adults in rural areas, for conditions such as chronic pain and dementia, and the role of pharmacists in care provision.

Frank Federico, RPh - Executive Director, Strategic Partners, Institute for Healthcare Improvement (IHI)

Frank Federico, works in the areas of patient safety, application of reliability principles in health care, preventing surgical complications, and improving perinatal care. He is faculty for the IHI Patient Safety Executive Training Program and co-chaired a number of Patient Safety Collaboratives. Prior to joining IHI, Mr. Federico was the Program Director of the Office Practice Evaluation Program and a Loss Prevention/Patient Safety Specialist at Risk Management Foundation of the Harvard Affiliated Institutions, and Director of Pharmacy at Children’s Hospital, Boston.

He has authored numerous patient safety articles, co-authored a book chapter in Achieving Safe and Reliable Healthcare: Strategies and Solutions, and is an Executive Producer of “First, Do No Harm, Part 2: Taking the Lead.” Mr. Federico serves as Vice Chair of the National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP).

Frank Moriarty, BSc (Pharm), MPharm, PhD, MPSI

Postdoctoral researcher, honorary lecturer

Frank Moriarty is a research pharmacist and postdoctoral researcher at the HRB Centre for Primary Care Research at the Royal College of Surgeons in Ireland (RCSI). The HRB Centre is the national centre for research in primary care in Ireland and aims to enhance patient safety in terms of prescribing, diagnostic and therapeutic approaches to patient care by utilizing information and communication technology. Frank is also an honorary lecturer at School of Pharmacy, RCSI, and a visiting research fellow and medications group lead at The Irish Longitudinal Study on Ageing (TILDA). His research is primarily focused on using observational methods to evaluate medication safety and quality of care.

Ivy Oandason, MD, CCFP, MHSc, FCFP

Clinician-Educator/Researcher, Wilson Centre for Research in Education, University of Toronto
Director, the College of Family Physicians of Canada

Dr. Oandasan’s main focus of research has been in health profession education, specifically interprofessional education and family medicine education. She was the project lead for the literature review and environmental scan for Health Canada’s Interprofessional Education for Collaborative Patient Centered Practice Initiative in 2004, and a literature review on Effective Teamwork for the Canadian Health Sciences Research Foundation in 2005. Both projects created seminal documents used nationally and internationally to advance interprofessional education and interprofessional care.

James Conklin, PhD

Associate Professor, Applied Human Sciences at Concordia University

James Conklin is a professor, researcher and consultant whose work focuses on planned social change. From 2013 to 2016 he was co-leader of the knowledge translation and exchange team for the OPEN research program, which focused on transforming pharmacy practice in Ontario. James’s research and consulting relies on sensemaking and social learning frameworks and qualitative methods.

James won the 2016 Concordia University Research Communicator of the Year (National) award and the 2012 Alumni Award for Excellence in Teaching. James is an investigator at the Bruyere Research Institute in Ottawa, and is a researcher with engAGE, Concordia’s Centre for Research on Aging.

Johanna Trimble, Patient advocate

Like many, Johanna Trimble had a challenging experience with a family member in the healthcare system and sought to affect change for the better, not just for her family, but for many others. It was 2010 when Johanna began to share the compelling story about her mother-in-law, Fervid Trimble. The galvanizing patient narrative, Is Your Mom on Drugs, drew interest from many working in and connected to healthcare and since then Johanna has effectively used that interest to lead initiatives for change that have resulted in greater awareness and new tools. With unwavering passion, Johanna has sought out various mechanisms for having her voice heard and to engage others in addressing the dangers of overmedication of older adults.

Justin Turner, BPharm, MClinPharm, PhD

Senior Advisor, Science Strategy and the Canadian Deprescribing Network (CaDeN)

Justin Turner received a Bachelor of Pharmacy and a Masters of Clinical Pharmacy from University of South Australia, and a PhD from Monash University. Justin worked as a clinical pharmacist in hospitals across South Australia and the United Kingdom for several years before starting a community pharmacy in regional South Australia. In this role, he worked closely with local family physicians and Residential Aged Care Facilities. Working closely with older people in the community and in care facilities enhanced his passion for optimizing medication management in vulnerable older people.

Kevin Pottie, MD, MClSc, CCFP, FCFP

Kevin Pottie is an Associate Professor and practicing physician at the Departments of Family Medicine and Epidemiology & Community Medicine and Scientist at the Bruyere Research Institute, University of Ottawa, Canada. He co-led the evidence based GRADE methods for the Describing Guidelines and the PPI and Benzodiazepam guidelines. He is a currently leading a the European Centres for Disease Control Evidence Based Guidelines. In 2016, he won University of Ottawa article of the year for his CMAJ guidelines: Caring for a Syrian Refugee Family. He has published over 100 peer review papers and chapters including “Migrant Health” in Oxford Bibliographies and the Canadian Pediatric Society’s on-line resource: Caring for Kids New to Canada.

Lalitha Raman-Wilms, BScPhm, PharmD, FCSHP

Professor and Dean, College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba

Lalitha Raman-Wilms is the Dean, College of Pharmacy, at the University of Manitoba. Her research interests include management of polypharmacy in the elderly through deprescribing and medication optimization, as well as curriculum development. She has many years of patient care experience in hospital and in community practice. Lalitha has been recognized for her teaching through many awards, including the Association of Faculties of Pharmacy of Canada’s National Award for Excellence in Education. She is editor-in-chief of a consumer information book on medications: CPhA’s Guide to Drugs in Canada. She is the past president of the Association of Faculties of Pharmacy of Canada and is a fellow of the Canadian Society of Hospital Pharmacists.

Lisa Dolovich, BScPhm, PharmD, MSc

Dr. Lisa Dolovich is a Professor and holds the Ontario College of Pharmacists Professor in Pharmacy Practice at the Leslie Dan Faculty of Pharmacy at the University of Toronto.

Lisa is also a Professor (part-time) in the Department of Family Medicine at McMaster University and an Associate Professor (Adjunct) with the School of Pharmacy at the University of Waterloo. The areas of focus for her research work and expertise include the pharmacist integration into primary care team based practice, expanded professional pharmacy services, the patient perspective about using or deciding to use medications, and evaluating the implementation including clinical and policy relevance of complex interventions that can improve the delivery and outcomes of primary health care including medication prescribing and patient medication taking behaviour. Her work is focused mainly in the community based primary health care setting including how individuals manage their health where they live. She is particularly interested in how a person’s goals, priorities, needs and risks can be better understood by the health care team as a driver for improvements in health care delivery and health.

Lisa McCarthy, BScPhm, PharmD, MSc

Scientist, Women’s College Research Institute at Women’s College Hospital

Assistant Professor (status), Leslie Dan Faculty of Pharmacy and Department of Family and Community Medicine, Faculty of Medicine, University of Toronto

Lisa leads the Pharmacist prescribing project, a study that explores both existing and potential avenues for pharmacist independent prescribing in Ontario. She is also a member of OPEN’s Deprescribing guidelines for the elderly project, the Pharmacist services evaluation project and the Gender and vulnerable population’s team. Lisa is an Assistant Professor (status) at the Leslie Dan Faculty of Pharmacy and is cross-appointed to the Department of Family and Community Medicine at the University of Toronto. She is also a Pharmacy Scientist with the Women’s College Research Institute at Women’s College Hospital in Toronto. Her research focuses on optimizing medication effectiveness and safety in the ambulatory care setting and evaluating novel models of ambulatory care practice.

Lise M. Bjerre, MD, PhD, CCFP

Assistant Professor, University of Ottawa

Lise Bjerre is an epidemiologist and a family physician with a PhD (Epidemiology, McGill University), Dr.med. (University of Göttingen, Germany) and Doctor of Medicine (McGill University). She is a researcher with the Department of Family Medicine, with a cross-appointment to the School of Epidemilogy, Public Health and Preventive Medicine at the University of Ottawa, a practicing family physician at the Civic Family Health Team of The Ottawa Hospital, and Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES).

Malcolm Maclure, ScD

Academic Chair in Patient Safety and Professor in the Department of Anesthesiology, Pharmacology and Therapeutics at UBC

Malcolm Maclure is a member of the Therapeutics Initiative at UBC and Canadian Deprescribing Network, with a special interest in de-prescribing in residential care. He serves as ex-officio member of the BC Patient Safety and Quality Council and is co-investigator and project director of the Surgical Quality Outcome Reports (SQOR) study. He leads the Patient Safety and Quality Theme, and the Health System and Leadership Theme, in curriculum renewal of the UBC Medical Undergraduate Program

Ned Pojskic, HonBSc, MSc, PhD

Pharmacy Strategy Leader, Green Shield Canada (GSC)

Ned Pojskic is the Pharmacy StrategyLeader at Green Shield Canada (GSC). In this role he is responsible for setting GSC’s strategic direction in pharmacy benefits management, including formulary design and management, pricing and policy. In addition, Ned is responsible for stakeholder relations with both the pharmacy and pharmaceutical industry. Ned brings a wealth of experience in policy, advocacy, and government relations through his previous role as the Director of Health Policy at the Ontario Pharmacists Association. Ned holds Masters and PhD degrees from the Department of Pharmaceutical Sciences at the University of Toronto. He is currently appointed as an Adjunct Professor (Status) at the Leslie Dan Faculty of Pharmacy in the University of Toronto.

Vittorio Maio, PharmD, MS, MSPH

Clinical Pharmacist and Research Professor of Population Health at Thomas Jefferson University, Philadelphia, PA

Vittorio Maio is Research Professor at the Thomas Jefferson University College of Population Health. He is also Director of the Health Economics & Outcomes Research Fellowship program. Dr. Maio’s research interests are in the areas of outcomes analysis and medication usage and policy. He has published more than 50 papers in peer-reviewed journals and presented his research at many national and international health conferences. Maio is Associate Editor of the American Journal of Medical Quality and serves as a reviewer for several professional journals, including JAMA-Internal Medicine, The Lancet, Pharmacoepidemiology & Drug Safety and Drugs & Aging. Dr. Maio received his Doctor of Pharmacy degree from the University of Perugia (Italy), took the Italian Pharmacist Board Certification and received both his MS in Pharmacology and his MS in Public Health from Thomas Jefferson University. He teaches Pharmacoepidemiology in the MS in Pharmacology program for the trainees in the National Institutes of Health (NIH) K30 Training Program.

Wade Thompson, PharmD MSc

Wade is a PhD fellow at the University of Southern Denmark in the Research Unit of General Practice. He is also a pharmacist with experience providing pharmaceutical care to older persons in both long-term care and primary care. He contributed to development of several deprescribing guidelines and completed MSc work related to proton pump inhibitor deprescribing.

Zubin Austin, BScPhm, MBA, MISc, PhD

Professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto
The Murray B. Koffler Chair in Pharmacy Management

Zubin Austin BScPhm MBA MISc PhD FCAHS is Professor and Murray Koffler Chair in Management at the Leslie Dan Faculty of Pharmacy, University of Toronto. His research focuses on the professional and personal development of the health human resources workforce, with particular interests related to internationally educated health professionals. He has published over 120 peer reviewed manuscripts and authored three reference texts. He has received numerous awards for his research from Canadian and international organizations, and in 2017 was installed as a Fellow of the Canadian Academy of Health Sciences in recognition of the impact of his work. He is also an award winning educator having received the Province of Ontario’s Leadership in Faculty Teaching Award, the University of Toronto’s President’s Teaching Award, and he has been named undergraduate Professor of the Year by students on 17 separate occasions.

Supported By:




Sponsored By:





Additional Information


Ottawa Conference and Event Centre
200 Coventry Rd, Ottawa, ON Canada K1K 4S3
+1 613 288 3450

Student Rates
We are pleased to offer a student rate of $75.00/day (includes access to all sessions and meals) for students who are not currently employed full-time. Please email deprescribing@bruyere.org for more information on how to register as a student.

How can I contact the organizer with questions?
If you have questions regarding registration or the symposium please email deprescribing@bruyere.org

What is the refund policy?
30 days or more before the event – full refund via Event Brite cancellation
Less than 30 days before the event – No refund (transfer to another individual only)

Booking Confirmations
Booking confirmation will be sent to you immediately for all on-line bookings. If you have not received an email confirmation within 24 hours of making the on-line booking, please contact the team at deprescribing@bruyere.org

Interested in sponsoring the symposium?
There are currently several sponsorship opportunities available for supporters and organizations that would be interested in being more involved in helping us make our first Evidence Based Deprescribing Guideline Symposium a success! Please contact Tammie at tquast@bruyere.org for more information and details on sponsorship.

Sign up for our newsletter

To receive deprescribing.org updates and news, subscribe to our periodic newsletter – deprescribing.org: Update

In the News

New Canadian Network Tackles Overprescribing

Cara Tannenbaum and Barb Farrell discuss CaDeN and ongoing research and initiatives that are helping curb risky prescription drug use among seniors in the Canadian Medical Association Journal (Sept 14th,...

Deprescribing as Important as Prescribing

Barb Farrell talks about the deprescribing guidelines and the work of the Bruyère Research Institute and the Canadian Deprescribing Network (CaDeN) in the Ottawa Citizen (Oct. 1st,...